Melinta Therapeutics

Melinta Therapeutics is an antibiotics-focused company.  The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.  The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.

Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Melinta Therapeutics (MLNT) Stock

Shares of Melinta Therapeutics Inc. shares were gaining more than 200% Wednesday, but a Jefferies analyst said the move is "overdone.

Jefferies: Move In Melinta Is 'Overdone'

Melinta Therapeutics news for Wednesday concerning approval from the U.S. Food and Drug Administration (FDA) has MLNT stock flying high.

Melinta Therapeutics News: Why MLNT Stock Is Skyrocketing Today

Melinta Therapeutics shares are trading higher after the company said the FDA accepted a supplemental New Drug Application (sNDA) for priority review of its BAXDELA sNDA for the treatment of community acquired bacterial pneumonia.

Melinta Therapeutics Shares Up 200% After FDA Accepts sNDA For Bacterial Pneumonia Drug

Shares of Melinta Therapeutics Inc.  more than doubled (up 128%) on heavy volume Wednesday, after the antibiotics developer said its supplemental new drug application (sNDA) for Baxdela was accepted by the U.S.

Melinta Therapeutics' stock rockets on heavy volume after FDA accepts sNDA for Baxdela

Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares nearly doubled early on Wednesday after the firm announced that the U.S.

Why This FDA Approval for Pneumonia Treatment Is So Huge

Melinta Therapeutics' (MLNT) CEO John Johnson on Q1 2019 Results - Earnings Call Transcript

Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 14.29% and -16.29%, respectively, for the quarter ended March 2019.

Melinta Therapeutics, Inc. (MLNT) Reports Q1 Loss, Misses Revenue Estimates

Melinta Therapeutics is now positioned to be the largest pure-play antibiotic company on the market, but the street has yet to show support for the stock.

News for Melinta Therapeutics Stock (MLNT)